摘要
目的评价盐酸埃克替尼在晚期复发非小细胞肺癌（non—smallcelllungcancer，NSCLC）中的疗效、安全性并探讨其疗效的影响因素。方法收集2009年3月-2013年2月我院收冶的65例接受盐酸埃克替尼治疗的晚期复发非小细胞肺癌患者的临床资料并进行回顾性分析。结果65例均可评价疗效，总有效率44．6％，疾病控制率78．4％。女性患者的有效率优干男性（58.3％vs27．6％，P=0．013）;二线治疗组的有效率和疾病控制率优于三线及以上组（有效率55．0％vs28．0％，P=0．033;疾病控制率87．5％vs64．0％，P=0．025）;一线含铂化疗疗效达PR／SD组的有效率优于一线化疗疗效PD者（53．5％vs23．5％，P=0．036）；有皮疹组的有效率和疾病控制率优于无皮疹组（有效率59．4％vs30.3％，P=0．018；疾病控制率93．8％vs63．6％，P=0．003）。EGFR敏感突变患者的有效率及疾病控制率均显著优于EGFR野生型患者（有效率65．4％vs11．1％，P=0．009；疾病控制率96．2％vs44．4％，P=0．003）;年龄三65岁与〈65岁，Ps评分〈2分与三2分，19外显子缺失突变组与21外显子L858R突变组间缓解率无统计学差异。EGFR敏感突变、不吸烟、皮疹、一线化疗达到疾病控制为疗效的独立影响因子。不良反应主要为轻度皮疹及腹泻。结论盐酸埃克替尼是治疗晚期复治NSCLC的有效药物，安全性好，尤其在携带敏感突变的患者中疗效更佳。
Objective To evaluate the efficacy of icotinib hydrochloride and explore influencing factors in patients with pretreated advanced non- small cell lung cancer （NSCLC）. Methods The clinical data of 65 NSCLC patients treated in Beijing Chest Hospital, Capital Medical University from March 2009 to February 2013 were retrospectively analyzed. Results The overall response rate was 44.6% and the disease control rate （DCR） was 78.4%. Response rate （RR） in female and those patients got disease control in lst-line chemotherapy were superior to male （RR 58.3% vs 27.6% , P=-0.013） and patients failed to lst-line chemotherapy （RR 53.5% vs 23.5%, P=0.036）, respectively. The RR and DCR in 2nd-line subgroup, rash subgroup and EGFR mutation carriers were superior to 〉 3rd-line subgroup （ RR 55.0% vs 28.0%, P =0.033 ; DCR 87.5% vs 64.0% , P=0.025）, without rash ones （RR 59.4% vs 30.3%, P=0.018 ;DCR 93.8% vs 63.6%, P=0.003） and EGFR wild-type patients （RR 65.4% vs 11.1% , P =0. 009 DCR 96.2% vs 44.4% , P =0. 003） , respectively. There was no statistical difference in RR and DCR between those age 〈65 and ≥ 65, or PS 〈2 and PS 〉 2. There was no statistical difference in RR and DCR between exon 19 deletion and exon 21 L858R mutations. EGFR mutation, no-smoking, rash and getting disease control in 1 st-line chemotherapy were the independent influencing factors for better efficacy. The side-effects were generally mild and consisted of rash and diarrhea. Conclusion Icotinib hydrochloride is effective and well tolerated in patients with pretreated advanced non-small-cell lung cancer and has better efficacy especially in EGFR mutation carriers.
出处
《结核病与胸部肿瘤》
2014年第4期247-250,共4页
Tuberculosis and Thoracic Tumor
关键词
盐酸埃克替尼
非小细胞肺癌
疗效
Icotinib hydrochloride
Non-small cell lung cancer
Efficacy
